NovAccess Global

NovAccess Global is a biopharmaceutical company accelerating the development of novel cancer diagnostics and treatments. Our goal is to discover, develop, and bring to market innovative drugs and medical devices to improve the quality of care for cancer and neurology patients. NovAccess Global is currently developing a cancer vaccine therapy to enhance patients' immune response to brain tumors. Our company has a new immunotherapy treatment for patients with glioblastoma multiforme, the most common adult brain tumor, which has a median survival of 15 months after diagnosis. Our patented technology aims to combine dendritic cell-based immunotherapy with a unique combination of Toll-like Receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against patients' tumors. Our platform technology focuses on enhancing patients' immune cells by leveraging antigens specific to their tumors to combat their unique cancers. The company has a cancer vaccine, a drug that stimulates or restores the immune system’s ability to fight existing cancer by boosting the body's natural defenses against cancer cells. This is a meaningful technology that can significantly improve the quality of life and prognosis for many brain tumor patients.